Zobrazeno 1 - 10
of 30
pro vyhledávání: '"James S Novak"'
Effect of endurance exercise on microRNAs in myositis skeletal muscle-A randomized controlled study.
Autor:
Jessica F Boehler, Marshall W Hogarth, Matthew D Barberio, James S Novak, Svetlana Ghimbovschi, Kristy J Brown, Li Alemo Munters, Ingela Loell, Yi-Wen Chen, Heather Gordish-Dressman, Helene Alexanderson, Ingrid E Lundberg, Kanneboyina Nagaraju
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183292 (2017)
To identify changes in skeletal muscle microRNA expression after endurance exercise and associate the identified microRNAs with mRNA and protein expression to disease-specific pathways in polymyositis (PM) and dermatomyositis (DM) patients.Following
Externí odkaz:
https://doaj.org/article/d90075eef8b740c6bdb09916a05214c1
Autor:
Davi A. G. Mázala, Ravi Hindupur, Young Jae Moon, Fatima Shaikh, Iteoluwakishi H. Gamu, Dhruv Alladi, Georgiana Panci, Michèle Weiss-Gayet, Bénédicte Chazaud, Terence A. Partridge, James S. Novak, Jyoti K. Jaiswal
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract Lack of dystrophin expression is the underlying genetic basis for Duchenne muscular dystrophy (DMD). However, disease severity varies between patients, based on specific genetic modifiers. D2-mdx is a model for severe DMD that exhibits exace
Externí odkaz:
https://doaj.org/article/ca9a535e1bfb4bc4a51860c19383424a
Autor:
Christopher R. Heier, Nikki M. McCormack, Christopher B. Tully, James S. Novak, Breanne L. Newell‐Stamper, Alan J. Russell, Alyson A. Fiorillo
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 14, Iss 2, Pp 940-954 (2023)
Abstract Background Becker muscular dystrophy (BMD) is a genetic neuromuscular disease of growing importance caused by in‐frame, partial loss‐of‐function mutations in the dystrophin (DMD) gene. BMD presents with reduced severity compared with D
Externí odkaz:
https://doaj.org/article/942efa9874ef477cb729dc344cea4ca6
Autor:
Michael Ogundele, Jesslyn S. Zhang, Mansi V. Goswami, Marissa L. Barbieri, Utkarsh J. Dang, James S. Novak, Eric P. Hoffman, Kanneboyina Nagaraju, CINRG-DNHS Investigators, Yetrib Hathout
Publikováno v:
Life, Vol 11, Iss 8, p 827 (2021)
Duchenne muscular dystrophy (DMD) is a progressive muscle disease involving complex skeletal muscle pathogenesis. The pathogenesis is triggered by sarcolemma instability due to the lack of dystrophin protein expression, leading to Ca2+ influx, muscle
Externí odkaz:
https://doaj.org/article/0d7db1a96ab9452987e5b9bd0f04eab0
Autor:
James S. Novak, Marshall W. Hogarth, Jessica F. Boehler, Marie Nearing, Maria C. Vila, Raul Heredia, Alyson A. Fiorillo, Aiping Zhang, Yetrib Hathout, Eric P. Hoffman, Jyoti K. Jaiswal, Kanneboyina Nagaraju, Sebahattin Cirak, Terence A. Partridge
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Exon skipping is a strategy for the treatment of Duchenne muscular dystrophy, but has variable efficacy. Here, the authors show that dystrophin restoration occurs preferentially in areas of myofiber regeneration, where antisense oligonucleotides are
Externí odkaz:
https://doaj.org/article/2bba740be75c451786064cc88308d9ee
Autor:
Davi A. G. Mázala, Ravi Hindupur, Young Jae Moon, Fatima Shaikh, Iteoluwakishi H. Gamu, Dhruv Alladi, Georgiana Panci, Michèle Weiss-Gayet, Bénédicte Chazaud, Terence A. Partridge, James S. Novak, Jyoti K. Jaiswal
Publikováno v:
bioRxiv
Lack of dystrophin is the genetic basis for the Duchenne muscular dystrophy (DMD). However, disease severity varies between patients, based on specific genetic modifiers. D2-mdxis a model for severe DMD that exhibits exacerbated muscle degeneration a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::712fed063137ff36abd44ef4d0667641
https://doi.org/10.1101/2023.03.27.534413
https://doi.org/10.1101/2023.03.27.534413
Autor:
Christopher B. Tully, Terence A. Partridge, Utkarsh J. Dang, Ravi Hindupur, Davi A. G. Mázala, James S. Novak, Kristy J. Brown, Yetrib Hathout, Emily H. Canessa, Alyson A. Fiorillo, Kanneboyina Nagaraju, Rita Spathis
Publikováno v:
Journal of Neuromuscular Diseases
Recently, the Food and Drug Administration granted accelerated approvals for four exon skipping therapies –Eteplirsen, Golodirsen, Viltolarsen, and Casimersen –for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeeee445cf10ae357bc01250c19e86ef
https://doi.org/10.3233/jnd-210696
https://doi.org/10.3233/jnd-210696
Autor:
Emily H. Canessa, Rita Spathis, James S. Novak, Aaron Beedle, Kanneboyina Nagaraju, Luca Bello, Elena Pegoraro, Eric P. Hoffman, Yetrib Hathout
Publikováno v:
Mass spectrometry reviewsREFERENCES.
The dystrophin-associated protein complex (DAPC) is a highly organized multiprotein complex that plays a pivotal role in muscle fiber structure integrity and cell signaling. The complex is composed of three distinct interacting subgroups, intracellul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b64de9d9b942c0ee4b827a291e519d37
https://pubmed.ncbi.nlm.nih.gov/36420714
https://pubmed.ncbi.nlm.nih.gov/36420714
Autor:
James S. Novak, Marshall W. Hogarth, Jessica F. Boehler, Marie Nearing, Maria C. Vila, Raul Heredia, Alyson A. Fiorillo, Aiping Zhang, Yetrib Hathout, Eric P. Hoffman, Jyoti K. Jaiswal, Kanneboyina Nagaraju, Sebahattin Cirak, Terence A. Partridge
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-1 (2018)
The originally published version of this Article contained an error in Figure 6. In panel b, the top graph (BrdU 21–24d) and the bottom graph (BrdU 28–31d) were inadvertently swapped. This error has now been corrected in both the PDF and HTML ver
Externí odkaz:
https://doaj.org/article/a9e3c5af6e8f42de973b74b8f858aefb
Autor:
Kanneboyina Nagaraju, Qi Long Lu, Melissa Morales, Yetrib Hathout, Umar Burki, James S. Novak, Aiping Zhang, Terence A. Partridge, Katie A. Edwards, Kathleen Tatum, Eric P. Hoffman, Margaret Benny Klimek, Jack H. Van der Mulen, James L Quinn, Alyson A. Fiorillo, John van den Anker, Volker Straub, Maria Candida Vila, Jessica F. Boehler
Publikováno v:
Journal of neuromuscular diseases. 8(s2)
Background: Phosphorodiamidate morpholino oligomer (PMO)-mediated exon skipping is currently used in clinical development to treat Duchenne muscular dystrophy (DMD), with four exon-skipping drugs achieving regulatory approval. Exon skipping elicits a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6be1d995f90f46a27d768d47909c46d
https://pubmed.ncbi.nlm.nih.gov/34569970
https://pubmed.ncbi.nlm.nih.gov/34569970